Actively Recruiting
Evaluation of the Pharmacogenetics and Personalized Medicine Program MedeA in the Extremadura Health Service Population Cohort
Led by Complejo Hospitalario Universitario de Badajoz · Updated on 2024-09-23
6445
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This observational study includes adults and some minors who receive care from the Extremadura Health Service. It focuses on patients treated with drugs that may cause significant side effects and aims to evaluate the implementation of the MedeA Pharmacogenetics and Personalized Medicine Program. No new treatments are given; instead, the study collects data based on usual clinical care and information from drug labels regarding genetic markers, interactions, and contraindications. Participants come from various medical fields such as oncology, mental health, cardiology, neurology, and others. The study does not involve any experimental drugs or procedures but gathers information naturally during routine care. It started in May 2021 and will continue until December 2024, assessing how the MedeA program is integrated into healthcare practice. During the study, participants provide consent and allow researchers to collect relevant data from their medical records. No additional interventions are performed, but information related to pharmacogenetic biomarkers and drug safety is monitored. The main outcome is an evaluation of the MedeA program's implementation by the end of 2024. Participants may be followed over time to track their treatment and outcomes without extra visits beyond usual care.
CONDITIONS
Brief Title
Evaluation of the Implementation of the Pharmacogenetics and Personalized Medicine Program "MedeA" in the Extremadura Health Service.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 years or older
- Minors under 12 years may participate with consent from both parents or guardians
- Minors aged 12 to 16 years may participate with proxy consent from one or both parents depending on circumstances
- Registered or attended by the Extremadura Health Service
- Able to communicate without language barriers or total dependency on another person
- Provide informed consent and agree to participate
You will not qualify if you...
- Failure to meet any inclusion criteria
- Refusal to join or continue in the study
- Difficulty with follow-up during the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to December 2024
Participants who undergo routine care are observed to evaluate the implementation of the Pharmacogenetics and Personalized Medicine Program MedeA in the Extremadura Health Service.
Trial Site Locations
Total: 1 location
1
Complejo Hospitalario Universitario de Badajoz
Badajoz, Spain, 06080
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
17
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here